TNXP
Tonix Pharmaceuticals Holding Corp.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Today, 4:43 PM
    • Tonix Pharmaceuticals (NASDAQ:TNXP) will eliminate the position of Chief Scientific Officer (CSO) effective December 31. Current CSO Bruce Daugherty, Ph.D., will resign at that time.
    • To ease the transition, Dr. Daugherty will receive a severance payment equal to one year's salary, health benefits for him and his family for one year and automatic acceleration of the vesting and exercisability of outstanding unvested stock awards that would have vested over the 12-month period.
    | Today, 4:43 PM
  • Thu, Nov. 10, 4:55 PM
    • Tonix Pharmaceuticals (NASDAQ:TNXP): Q3 EPS of -$0.29 beats by $0.05.
    • Cash and equivalents of $26.73M
    • Press Release
    | Thu, Nov. 10, 4:55 PM | 2 Comments
  • Wed, Oct. 26, 12:44 PM
    • Nano cap Tonix Pharmaceuticals (TNXP -21.2%) slumps on triple normal volume in response to its announcement of a public offering of 9.5M units at $0.55. Each unit consists of one share of common stock and one five-year warrant to purchase 1/2 share of common at $0.63.
    • Underwriters over-allotment is an additional 1.425M shares of stock and/or warrants to purchase 712.5K shares of stock at $0.6875.
    • Net proceeds will be ~$4.6M. Closing date is October 31.
    • Yesterday's close was $0.6201.
    | Wed, Oct. 26, 12:44 PM | 20 Comments
  • Fri, Sep. 9, 9:59 AM
    • Eli Lilly (NYSE:LLY) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $95 (20% upside) from $92.
    • Ligand Pharmaceuticals (NASDAQ:LGND) upgraded to Hold from Sell by Deutsche Bank. Price target raised to $110 (2% downside risk) from $105.
    • Gilead Sciences (NASDAQ:GILD) upgraded to Buy from Hold by Jefferies. Price target raised to $91 (16% upside). Morgan Stanley rates it Hold with a price target of $100 (27% upside).
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) upgraded to Outperform from Market Perform with a $66 price target by Oppenheimer.
    • Novo Nordisk (NYSE:NVO) downgraded to Neutral from Overweight by JPMorgan.
    • AbbVie (NYSE:ABBV) downgraded to Neutral from Overweight with a $73 (14% upside) price target by JPMorgan.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Buy by BTIG Research.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) downgraded to Neutral from Buy by Roth Capital.
    • Momenta Pharmaceuticals (NASDAQ:MNTA) downgraded to Sell from Hold with a $6 (48% downside risk) price target by Maxim Group.
    • Biogen (NASDAQ:BIIB) downgraded to Hold from Buy with a $323 (7% upside) price target by Jefferies.
    • Centene (NYSE:CNC) downgraded to Market Perform from Outperform with an $80 (19% upside) price target by Leerink Swann. Wedbush rates it Outperform with an $85 (26% upside) price target.
    | Fri, Sep. 9, 9:59 AM | 12 Comments
  • Tue, Sep. 6, 12:45 PM
    | Tue, Sep. 6, 12:45 PM
  • Tue, Sep. 6, 11:00 AM
    | Tue, Sep. 6, 11:00 AM | 1 Comment
  • Tue, Sep. 6, 9:14 AM
    | Tue, Sep. 6, 9:14 AM
  • Tue, Sep. 6, 7:56 AM
    • Tonix Pharmaceuticals (NASDAQ:TNXP) is down 16% premarket, albeit on only 900 shares, in response to its announcement that its Phase 3 clinical trial, AFFIRM, assessing lead product candidate TNX-102 SL (cyclobenzaprine HCl sublingual tablets), 2.8 mg, for the treatment of fibromyalgia failed to achieve its primary endpoint of a statistically valid proportion of subjects who reported at least a 30% reduction in pain from baseline to Week 12 (p=0.095). An unexpected imbalance in patient discontinuations unrelated to efficacy and tolerability was the culprit, although almost 10% of the discontinuations were attributed to an adverse event (7.6%) or lack of efficacy (2.3%).
    • According to the company, TNX-102 SL showed statistically significant effects on pain when analyzed by other statistical approaches that assessed global improvement (Patient Global Impression of Change or PGIC) and a range of fibromyalgia symptoms and function (Fibromyalgia Impact Questionnaire-Revised or FIQ-R). It adds that treatment with TNX-102 SL showed clear evidence of improving sleep quality as measured by the daily diary and PROMIS sleep disturbance scale.
    • Despite the encouraging data from certain perspectives, Tonix will terminate the development of TNX-102 SL for fibromyalgia and focus its resources on the post-traumatic stress disorder (PTSD) indication.
    • Cyclobenzaprine, branded as Flexeril, was cleared by the FDA in August, 1977 for the treatment of muscle spasms. The value proposition of the sublingual formulation is decreased exposure, due to avoidance of first-pass metabolism, to the active metabolite norcylcobenzaprine, less desirable due to its long plasma half-life. The proposed trade name of the product is Tonmya.
    • Previously: Tonix Pharma up 16% premarket on advancement on TNX-102 SL in PTSD (Aug. 29)
    | Tue, Sep. 6, 7:56 AM | 40 Comments
  • Mon, Aug. 29, 9:13 AM
    | Mon, Aug. 29, 9:13 AM
  • Mon, Aug. 29, 9:02 AM
    • Thinly traded nano cap Tonix Pharmaceuticals (NASDAQ:TNXP) is up 16% premarket on robust volume in response to its announcement of a clear path to registration for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of post-traumatic stress disorder (PTSD).
    • Based on the written minutes received from the FDA from its End-of-Phase 2/Pre-Phase 3 meeting, the agency confirmed that positive results from two Phase 3 trials along with safety studies should be sufficient to demonstrate efficacy for PTSD. One Phase 3 will focus on military PTSD and the other in civilian PTSD. The former should commence in Q1 2017 and the latter will follow a bit later. The primary efficacy endpoints will be the same at the AtEase Phase 2: the mean change from baseline in the severity of PTSD symptoms at Week 12 as measured by a scale called CAPS-5.
    • In addition, the FDA agreed that the company's CMC (chemistry, manufacturing and controls) and nonclinical studies it previously accepted for the fibromyalgia NDA will be valid for the NDA for PTSD.
    • Cyclobenzaprine, branded as Flexeril, was cleared by the FDA in August, 1977 for the treatment of muscle spasms. The value proposition of the sublingual formulation is decreased exposure, due to avoidance of first-pass metabolism, to the active metabolite norcylcobenzaprine, less desirable due to its long plasma half-life. The proposed trade name of the product is Tonmya.
    • Read now Tonix's Findings About Patient Subgroups Can Mislead: How Investors Can Tell What's Real 
    | Mon, Aug. 29, 9:02 AM | 12 Comments
  • Mon, Aug. 8, 7:10 AM
    • Tonix Pharmaceuticals (NASDAQ:TNXP): Q2 EPS of -$0.50 beats by $0.05.
    • Cash and cash equivalents of $31.2M.
    • Press Release
    | Mon, Aug. 8, 7:10 AM | 5 Comments
  • Thu, Jun. 16, 11:00 AM
    | Thu, Jun. 16, 11:00 AM | 1 Comment
  • Thu, Jun. 16, 9:17 AM
    | Thu, Jun. 16, 9:17 AM | 5 Comments
  • Wed, Jun. 15, 5:32 PM
    | Wed, Jun. 15, 5:32 PM | 13 Comments
  • Wed, Jun. 15, 4:06 PM
    • Tonix Pharmaceuticals (NASDAQ:TNXP) commences a public offering of common stock. Price, volume and terms have yet to be announced. Shares are off 15% after hours on light volume.
    • Update: The offering is 5M shares at $2 per share. Underwriters over-allotment is an additional 750K shares. Closing date is June 21. Net proceeds will fund the continued development of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia and post-traumatic stress disorder, the advancement of other pipeline candidates, working capital and general corporate purposes. Shares are down 21% premarket on increased volume.
    | Wed, Jun. 15, 4:06 PM | 17 Comments
  • Fri, Jun. 3, 5:36 PM
    • Top gainers, as of 5.25 p.m.: VBLT +32.2%. GRMN +12.1%. BG +8.0%. TK +2.9%. TNXP +2.4%.
    • Top losers, as of 5.25p.m.: MGA -13.2%. AUY -4.2%. OUTR -3.0%. RF -2.4%. LBIO -2.1%.
    | Fri, Jun. 3, 5:36 PM | 7 Comments